FDA Approves New Oral Treatment for Herpes Simplex Virus Lesions

The FDA has approved pritelivir (Hovilpri) oral tablets for treating mucocutaneous herpes simplex virus lesions in adults. This new medication is specifically for patients with weakened immune systems who have not responded to existing therapies like acyclovir, valacyclovir, or famciclovir. The approval addresses a significant unmet medical need for individuals with resistant HSV infections.